Yuki, N; Watanabe, H; Nakajima, T; Späth, P J (2011). IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. Journal of neurology, neurosurgery and psychiatry, 82(1), pp. 87-91. London: BMJ Publishing Group 10.1136/jnnp.2010.205856
Full text not available from this repository. (Request a copy)The pathogenesis of multifocal motor neuropathy (MMN) has yet to be established. MMN patients often carry anti-GM1 IgM antibodies, suggesting an autoimmune process involving complement. Intravenous immunoglobulin (IVIG) is the first line treatment, but its action mechanism is unknown.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology |
UniBE Contributor: |
Späth, Peter Julius |
ISSN: |
0022-3050 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:09 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1136/jnnp.2010.205856 |
PubMed ID: |
20667861 |
Web of Science ID: |
000285183000021 |
URI: |
https://boris.unibe.ch/id/eprint/901 (FactScience: 201215) |
Actions (login required)
 |
Edit item |